Jasper Therapeutics Inc JSPR.OQ JSPR.O is expected to show no change in quarterly revenue when it reports results on November 5 (estimated) for the period ending September 30 2025
LSEG's mean analyst estimate for Jasper Therapeutics Inc is for a loss of $1.21 per share.
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy," 3 "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for Jasper Therapeutics Inc is $10.50, about 78.3% above its last closing price of $2.28
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Jun. 30 2025 | -1.34 | -1.33 | -1.74 | Missed | -31.2 |
Mar. 31 2025 | -1.34 | -1.31 | -1.41 | Missed | -7.4 |
Dec. 31 2024 | -1.23 | -1.23 | -1.62 | Missed | -31.7 |
Sep. 30 2024 | -1.08 | -1.07 | -1.24 | Missed | -15.7 |
Jun. 30 2024 | -1.08 | -1.09 | -0.97 | Beat | 10.9 |
Mar. 31 2024 | -1.23 | -1.22 | -1.03 | Beat | 15.9 |
Dec. 31 2023 | -1.60 | -1.61 | -1.50 | Beat | 7.1 |
Sep. 30 2023 | -1.53 | -1.55 | -1.60 | Missed | -3.1 |
This summary was machine generated November 3 at 15:00 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)